Intended for healthcare professionals

CCBYNC Open access

Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study

BMJ 2020; 369 doi: (Published 29 April 2020) Cite this as: BMJ 2020;369:m1186

Linked Editorial

SGLT2 inhibitors and kidney outcomes in the real world

Linked Analysis

Communicating emerging risks of SGLT2 inhibitors